Yes these are speculations but my hinking is as follows;

I've seen the zen3694 data presented and the follow up analysis by BDAZ and in my mind it looks like there are a few positive cases which may in fact in a large trial be significant but the results looked mixed to me.

I've not seen any recent updates on the trail.

The $10 million financing has not been completed. I believe it will be based on Don's history of financing success but right now things are uncertain to me.

As I said, from my perspective the ABBVie ABBV-744 trial is positive in the sense that it is clear that a very large BP is focused on selective BET inhibitors hence provides legitimacy for both apabetalone and Zenith in my opinion.

It is also positive in the sense that ABBV-744 is being trialed in prostate cancer which to me is a bit of a surprise.

Hence, as bear pointed out, it may have implications for apabetalone.

So these are my opinions...the way I see things now.

Toinv